News

Targeting research in cognitive impairment in epilepsy primarily on seizures themselves suggests that a patient’s comorbid problems will resolve with seizure control, though that is not always the case.

The guidelines recommend that patients with MS receive their recommended vaccines, including that for yearly influenza. Additionally, they noted that no evidence exists that suggests vaccination increases the risk of MS exacerbation.

As new dual orexin receptor antagonists become available to treat sleep disorders, time will tell whether this new class of drugs will fulfill its promise for a disorder plagued by underdiagnosis and indifference.

After being approved in Japan in 2013, the selective adenosine A 2A receptor antagonist was given the OK as an add-on to levodopa/carbidopa treatment in adults with Parkinson disease.

The director of comprehensive epilepsy center and professor of neurology at Thomas Jefferson University spoke to the evolution of epilepsy interventions over the last decade and its effect on the level of care for patients.

US WorldMeds rimabotulinumtoxinB injection showed significant decreases in sialorrhea symptoms with a single treatment as soon as the first week, lasting up to 3 months in clinical studies.

Interest in advancing research in stroke therapeutics has historically come in fits and starts. Now with intravenous tPA and thrombectomy in regular use, experts are looking to get a step ahead of the damage.

The professor of age-related diseases and dean of the University of Exeter Medical School discussed the need for improvement in nursing home care for those with dementia.

Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.

Neurology News Network for the week ending August 24, 2019.

NeurologyLive Editor in Chief Stephen D. Silberstein, MD discusses the importance of reaching a treatment effect that makes a significant difference in patients' lives.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.

The professor of neurology at the Icahn School of Medicine at Mount Sinai discussed what still needs to be done to clarify medical marijuana’s position in medicine.

A 23-year-old male college student presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.

New findings have suggested dementia is a result of worsened white matter rarefaction, phosphorylated tau, and arteriolosclerosis due to repeated head trauma in former football players with CTE.

Boston Scientific’s Vercise Gevia deep brain stimulation system labels will allow for clinical use of stimulation during full-body MRI in patients with Parkinson disease, with an improved battery.